Your session is about to expire
← Back to Search
JNJ-77242113 for Plaque Psoriasis (FRONTIER 2 Trial)
FRONTIER 2 Trial Summary
This trial will study the long-term effects of JNJ-77242113 on moderate-to-severe plaque psoriasis.
- Plaque Psoriasis
FRONTIER 2 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowFRONTIER 2 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.FRONTIER 2 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Group 1: JNJ-77242113 Dose 1 Once Daily (QD)
- Group 2: Group 2: JNJ-77242113 Dose 2 QD
- Group 3: Group 3: JNJ-77242113 Dose 3 QD
- Group 4: Group 4: JNJ-77242113 Dose 1 Twice Daily (BID)
- Group 5: Group 5: JNJ-77242113 Dose 3 BID
- Group 6: Group 6: JNJ-77242113 Dose 3 QD
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
What are the potential risks associated with taking JNJ-77242113?
"JNJ-77242113's safety was rated a 2 because there is some evidence attesting to its safety, but no data yet confirming its efficacy in Phase 2 of the trial."
Are people currently being signed up to participate in this experiment?
"That is correct. The information available on clinicaltrials.gov confirms that this study, which was first advertised on 6/10/2022, is still recruiting patients. In total, they are hoping to enroll 228 individuals at 20 different research sites."
Are there any research facilities in North America testing this new treatment?
"To lessen the burden of travel, patients are encouraged to select a clinical trial site from the 20 locations that is nearest to them. Some of these 20 sites include cities such as Waterloo, Hamilton and Montreal."
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
What site did they apply to?
How many prior treatments have patients received?
What questions have other patients asked about this trial?
Why did patients apply to this trial?
How responsive is this trial?
Most responsive sites:
- Indiana Clinical Trial Center: < 48 hours
- University of Pittsburgh Department of Dermatology: < 48 hours
Average response time
- < 2 Days
Typically responds via
Share this study with friends
Copy Link
Messenger